Arctic Bioscience (ABS) Stock Overview
A clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ABS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Arctic Bioscience AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 3.24 |
| 52 Week High | NOK 7.45 |
| 52 Week Low | NOK 1.78 |
| Beta | 1.3 |
| 1 Month Change | -11.23% |
| 3 Month Change | -2.70% |
| 1 Year Change | 69.63% |
| 3 Year Change | -74.39% |
| 5 Year Change | n/a |
| Change since IPO | -88.22% |
Recent News & Updates
Shareholder Returns
| ABS | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -1.8% | 11.3% | 1.9% |
| 1Y | 69.6% | 34.7% | 11.2% |
Return vs Industry: ABS exceeded the Norwegian Biotechs industry which returned 34.7% over the past year.
Return vs Market: ABS exceeded the Norwegian Market which returned 11.2% over the past year.
Price Volatility
| ABS volatility | |
|---|---|
| ABS Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in NO Market | 10.8% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: ABS's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: ABS's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 22 | Christer Valderhaug | www.arctic-bioscience.com |
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand name.
Arctic Bioscience AS Fundamentals Summary
| ABS fundamental statistics | |
|---|---|
| Market cap | NOK 87.34m |
| Earnings (TTM) | -NOK 43.36m |
| Revenue (TTM) | NOK 45.90m |
Is ABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABS income statement (TTM) | |
|---|---|
| Revenue | NOK 45.90m |
| Cost of Revenue | NOK 31.46m |
| Gross Profit | NOK 14.44m |
| Other Expenses | NOK 57.80m |
| Earnings | -NOK 43.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 31.45% |
| Net Profit Margin | -94.48% |
| Debt/Equity Ratio | 20.0% |
How did ABS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/25 02:02 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arctic Bioscience AS is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrik Ling | DNB Carnegie |
| Geir Holom | DNB Carnegie |